4C LABS has received a licence to cultivate medical cannabis by the Bailiwick of Guernsey Cannabis Agency (BGCA).
4C LABS received the first medical cannabis cultivation licence to be granted in Guernsey after its application was reviewed jointly by the BGCA and the UK Home Office.
The new company, which is building a vertically integrated infrastructure for producing and delivering cannabis therapeutics in the UK and the EU, will now begin the construction of its 40,000 sq ft pharmaceutical-grade indoor cultivation facility ion the island. 4C said that the facility will utilise organic cultivation techniques underpinned by modular design and automation, which is based on two decades of cannabis genetics that have been developed alongside the establishment of the Canadian medical cannabis market.
CEO of 4C LABS, Greg Dobbin, commented: “4C LABS was established in 2018 to cultivate and process cannabis-based medical products which address specific medical conditions to improve patients’ quality of life.
“We are delighted that with the approval of our cultivation licence, we can take the next steps in the development of our business and our vision to cultivate GMP craft medical cannabis, and establish a series of medical clinics accessed through a user-friendly technology platform to better service patients.
“We are seeking to lower the cost of cannabis-based therapeutics and improve efficiency in access for patients in the UK and Channel Islands, operating within the regulatory framework and with a core focus on patient safety. A further objective is, through our genetics library and our unique cultivation technologies, to improve the quality of flower from that which is currently available in the UK.
“Poised to be at the forefront of the development of the Medical Cannabis industry in the UK, we are also seeking to broaden our investor base as we develop and execute our growth strategy.”
4C has said it is positioned to begin cultivation in 2022, with the first 4C LABS Medical Flower therapeutics available in the first quarter of 2023.
[activecampaign form=31]
